Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeuticsReview Published on 2022-10-012023-07-10 Journal: Expert opinion on investigational drugs [Category] COVID19(2023년), [키워드] Dexamethasone guidelines randomized trials Remdesivir SARS-CoV-2 [DOI] 10.1080/13543784.2022.2120801 [Article Type] Review
Evaluation of the efficacy of oral nano-silymarin formulation in hospitalized patients with COVID-19: A double-blind placebo-controlled clinical trialArticle Published on 2022-10-012022-11-15 Journal: Phytotherapy research : PTR [Category] COVID19(2023년), SARS, 치료제, [키워드] alanine aminotransferase Anti-viral Antiviral assigned baseline clinical trial Concomitant COVID-19 cytokine release Cytokine release syndrome Dexamethasone dosage double-blind Effect effective Effectiveness Efficacy Evidence follow-up period gel Hospitalization hospitalized patient Laboratory Laboratory parameters lack liver enzyme management outbreak pandemic participant Patient patients with COVID-19 placebo group placebo-controlled clinical trial receiving Remdesivir sample sizes SARS-CoV-2 significant difference significantly silymarin Symptom the placebo group therapeutic strategy Treatment treatment group two group viral disease were assessed [DOI] 10.1002/ptr.7537 PMC 바로가기
Utility Of Inflammatory Markers For Tocilizumab In Covid-19 Patients: A Single-Site Retrospective StudyArticle Published on 2022-10-012023-07-11 Journal: Journal of Ayub Medical College, Abbottabad : JAMC [Category] COVID19(2023년), [키워드] COVID-19 CRP. D-dimer Dexamethasone ferritin inflammatory markers Pakistan Tocilizumab [DOI] 10.55519/JAMC-04-10565
Are the Current Processes and Regulations Fit for Purpose to Deliver Novel Therapies During Pandemics? A Perspective on COVID-19 from the UKArticle Published on 2022-10-012022-11-16 Journal: Pharmaceutical medicine [Category] 신약개발, [키워드] activities adaptive approval arise contribute country COVID-19 COVID-19 pandemic current develop Dexamethasone ENhance flexible Health involved lesson Medicines multi-arm novel Pandemics question rare diseases RECOVERY trial reduce Regulation Regulatory regulatory pathways shown Stress therapy Trial trials UK Medicine United Kingdom urgency [DOI] 10.1007/s40290-022-00439-7 PMC 바로가기
Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United StatesArticle Published on 2022-10-012023-07-10 Journal: Advances in therapy [Category] COVID19(2023년), [키워드] comparison Dexamethasone Effectiveness Premier Health Database United States [DOI] 10.1007/s12325-022-02267-2 PMC 바로가기
Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19Research article Published on 2022-10-012022-10-05 Journal: International Journal of Environmental Research an [Category] COVID19(2023년), SARS, 바이오마커, 변종, 유전자 메커니즘, 임상, 진단, 치료기술, [키워드] 95% CI Activation adjusted adjusted odds ratio aggregation Alpha Analysis application B.1.1.7 Bath biochemical Biomarkers biomarkers of inflammation biopsy changes clinical factors clinical outcomes clinically Coagulation Cohort Complication correlation Council COVID-19 death develop Dexamethasone diagnostic Direct driving dysregulation of coagulation Engineering evaluated facilitate finding foundation funding hazard ratio heart hospital identify in-hospital mortality indicated Inflammation investigated mammary marker myocardial injury National Health Service NHS NIHR Non-invasive outcome Oxford parameters Pathways Patient patients with COVID-19 perivascular Platelet platform predict produced Prognostic value pulmonary angiography pulmonary CT representing respond responsible risk RNA sequencing data SARS-CoV-2 variant Science sensitivity analysis targeted therapy therapeutic target transcriptional transcriptomic Treatment Trial validation study variant vascular inflammation Wellcome Trust Whole blood wild-type SARS-CoV-2 with COVID-19 [DOI] 10.1016/S2589-7500(22)00132-7 [Article Type] Research article
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UKArticle Published on 2022-09-292022-11-15 Journal: Clinical and experimental immunology [Category] SARS, 진단, [키워드] access age anti-SARS-CoV-2 baseline co-morbidity Cohort Combination convalescent plasma COVID-19 COVID-19 treatment CVID demonstrated Dexamethasone died Fatality rate General population high risk hospital Hypogammaglobulinemia IFR immunodeficiency inborn errors of immunity increased the risk Increasing individual Infection Lymphocyte count lymphopenia monotherapy Mortality network outcome overall mortality Patient PID Primary immunodeficiencies receiving REGN-CoV2 Remdesivir reported risk factor SARS-CoV-2 SARS-COV-2 infection secondary immunodeficiencies. therapeutic Tocilizumab Treatment United Kingdom [DOI] 10.1093/cei/uxac008 PMC 바로가기
Could Endogenous Glucocorticoids Influence SARS-CoV-2 Infectivity?Article Published on 2022-09-212022-11-15 Journal: Cells [Category] SARS, 변종, 치료제, [키워드] ACE2 ACE2 (angiotensin converting enzyme 2) Affect alteration analogues Antiviral component conformational coronavirus coronavirus diseases cortisol COVID-19 Deleterious Dexamethasone endogenous enzyme glucocorticoid Glucocorticoids groups Host Immunological disorders Infection influence inhibit SARS-CoV-2 Innate immunity Interaction mechanism outcome pathogen produced PROTECT Protein SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 receptor Signal transduction spike Spike protein stimulate subunit surface protein target cells variant [DOI] 10.3390/cells11192955 PMC 바로가기
Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trialArticle Published on 2022-09-172022-10-06 Journal: EClinicalMedicine [Category] 진단, [키워드] 1:1 95 % CI Activation addition Administered adverse event approach assigned Basel blockade BMI canakinumab Clinical outcome contributing to COVID-19 CRP Dexamethasone diabetes died dose double-blind dropped drug Efficacy foundation glycaemic control higher risk hospitalised Hospitalization Hyperinflammatory ICU IL-1beta IL-1β IL-6 IMPROVE Inflammasome innate immune system interleukin-1β intravenous dose less medication multicenter multicentre Novartis Obesitiy. obesity outcome participant Patient patients treated patients with COVID-19 Placebo placebo group placebo-controlled trial primary analysis randomised randomization Randomly reduction Registered reported required SARS-CoV2 SARS-CoV2 infection Science Seven severe COVID-19 significantly Standard-of-care statistically significant statistically significant difference survival Switzerland systemic inflammation tested treated Treatment type 2 diabete university Ventilation with COVID-19 [DOI] 10.1016/j.eclinm.2022.101649 PMC 바로가기 [Article Type] Article
Longitudinal assessment of systemic steroid therapy on hyperinflammatory endothelial biomarker profiles and serology responses of COVID-19 patientsArticle Published on 2022-09-082022-11-15 Journal: Journal of Translational Medicine [Category] SARS, 바이오마커, [키워드] Abstract Biomarker COVID-19 COVID-19 patient CXCL9 cytokine Dexamethasone endothelial Hyperinflammatory Inflammation longitudinal profile response serology therapy [DOI] 10.1186/s12967-022-03583-5 PMC 바로가기